Acute Ischemic Stroke is a new study from Decision Resources, Inc., that examines the significant unmet needs in the management of ischemic stroke (IS), and evaluates the considerable hurdles to the development of effective therapies. Because only one agent is approved for acute IS (the thrombolytic agent recombinant tissue plasminogen activator [rt-PA]), and it is administered to less than 2% of the incident cases, a safe, effective drug could significantly impact the market.

(Photo: )

News from the IS pipeline over the past three years has been disappointing. The failures of trials of several high profile investigational neuroprotective drugs have left the door open for an agent capable of filling the unmet needs in acute IS treatment. Pharmaceutical manufacturers are aware of the problems that have plagued other agents and have taken steps to avoid these obstacles by improving clinical trial design. One bright spot on the horizon is Millennium Pharmaceutical's proteasome inhibitor LDP-519 (PS-519). Although the agent has just entered Phase I trials, LDP-519 has captured the attention of thought leaders and industry watchers worldwide because it has unique characteristics that could be beneficial if its efficacy and safety are borne out.

Based on interviews with experts from the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), Acute Ischemic Stroke highlights critical areas of unmet need in the treatment of acute IS and in clinical trial design, and evaluates the potential of novel strategies, such as Millenium's proteasome inhibitor LDP- 519 and others, to overcome these hurdles.

Acute Ischemic Stroke offers invaluable market intelligence for pharmaceutical companies competing in this market, and is a part of Cognos, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in research publications and advisory services designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

   Contact Frank Sama, 781.296.2553 (tel), 781.296.2525 (fax), or    In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347    (fax), or    In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel),    +81.3.5401.2617 (fax), or 



AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,

Decision Resources Study Finds Lucrative Opportunities Await Developers of Novel Hormone Replacement Therapies

View Now